After just 2 years, Ironwood Pharmaceuticals has decided to terminate its licence agreement with AstraZeneca to develop, commercialise and manufacture products containing lesinurad as an active ingredient, including Duzallo® (lesinurad/allopurinol) and Zurampic® (lesinurad), in the US. The news follows below par market performance for Zurampic since its October 2016 launch, leaving Ironwood with no choice but to end the collaboration and focus its efforts on higher return opportunities and growth drivers. Other deals to be terminated in recent months include Novartis’ licensing agreement with AVEO Pharmaceuticals for AV-380 and Purdue Pharma’s agreement with Shionogi for the US co-commercialisation of Symproic® (naldemedine).